Third-line Treatment of Gefitinib in NSCLC Patients Who Had Received First-line Gefitinib With EGFR 19del/L858R Mutation and Tumor Progression After the Second-line Chemotherapy: a Single-arm, Prospective, Multi-center and Exploratory Study
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2019
Price : $35 *
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 02 Jun 2017 Primary endpoint (Disease Control Rate (DCR)) has been met, as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.